SetPoint’s CEO Simhambhatla gives DT Minn preview on bringing neurotechnologies to new markets
In this episode of the DeviceTalks Weekly Podcast, SetPoint Medical CEO Murthy Simhambhatla gives listeners an audio glimpse of what attendees at DeviceTalks Minnesota will hear during the Bringing NeuroTechnologies to New Markets panel.
As he explains in this interview, Simhambhatla—an experienced MedTech executive—was initially skeptical of SetPoint’s potential after being invited to lead the company. But the more he read, the more he became convinced the vagal stimulator could help fight inflammation. “Cytokines don’t lie,” he said. Today, SetPoint Medical has FDA approval, is building a commercial plan, and is considering future financing, including a possible IPO.
This episode is sponsored by DeviceTalks Minnesota. Go to Minnesota.DeviceTalks.com to see the agenda. Remember to use the code DTM25 to save 25% on new registrations.
We also get a visit to our FOMO Studios from Saul Marquez, CEO of Outcome Rocket, a market research and end-to-end marketing execution agency that helps medtech and health tech organizations grow their impact and accelerate growth. See more and download the report we discuss here: https://www.outcomesrocket.com/
Finally, MassDevice Editor Chris Newmarker shares this week’s top newsmakers from MassDevice—Abbott, Johnson & Johnson MedTech, Boston Scientific, Medtronic, Pulnovo, and CathWorks.
***
Enjoy the show? Follow DeviceTalks Weekly on all major podcast players + Follow us on YouTube.com/@DeviceTalks to ensure you never miss an episode.
Want access to the complete DeviceTalks Podcast Network (DTPN)? Follow us today at https://devicetalks.castos.com/subscribe
